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Abstract
Clinical practice guidelines are ubiquitous and are developed to provide recommendations for the management of
many diseases, including chronic obstructive pulmonary disease. The development of these guidelines is burdensome,
demanding a significant investment of time and money. In Europe, the majority of countries develop their own national
guidelines, despite the potential for overlap or duplication of effort. A concerted effort and consolidation of resources
between countries may alleviate the resource-intensity of maintaining individual national guidelines. Despite significant
resource investment into the development and maintenance of clinical practice guidelines, their implementation is
suboptimal. Effective strategies of guideline dissemination must be given more consideration, to ensure adequate
implementation and improved patient care management in the future.
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Background
The ultimate treatment goals in chronic obstructive pul-
monary disease (COPD) management remain uniform
across the majority of national and international COPD
clinical practice guidelines (CPGs), and include reduced
symptoms, reduced exacerbation risk and improved
quality of life [1]. To achieve these goals, CPGs require
regular updates with recent and relevant state-of-the-art
medical and scientific developments. Guidelines strive to
improve the quality of healthcare and to reduce varia-
tions in the treatment and management of COPD [2].
Clinical practice guidelines provide recommendations
on patient management based on available evidence and,
in certain cases, educated opinion where there is no dir-
ect evidence available [3]. The quality of the available
evidence and the intended audience of CPGs remain
core considerations for their development [4]. In recent
years, CPGs have further evolved in response to an
increasing recognition of the need for more stringent,
systematic approaches when recommending specific
therapeutic interventions or strategies [5]. The importance
of rigorous processes to ensure that only accurate and ap-
propriate treatment recommendations are made is now
well-accepted among professional scientific societies. In
fact, standards to guide the preparation of CPGs are now
available [6]. However, little attention is afforded to the
challenges and pitfalls associated with the development of
such documents.
A concerted effort between multiple stakeholders is
needed to ensure precise, practical and up-to-date
clinical recommendations for the diagnosis and optimal
management of COPD. Guidelines must be locally
relevant; therefore local expert stakeholders should offer
local proposals, while referring to global evidence-based
documents.
This review article highlights the challenges associated
with the development and implementation of national
CPGs for COPD in Europe and Russia.
Current challenges associated with the development of
guidelines
Important advances in the methodologies used for the
development of CPGs have been made in recent years.
These include the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) guides [7].
GRADE provides a transparent, systematic approach to
review available evidence and rate its quality, in order to
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make recommendations of graded strength based on the
degree of confidence in the benefit-risk-cost ratio and ap-
plicability of the strategies of interest. GRADE is best used
in response to defined key clinical (population/interven-
tion/comparator/outcome [PICO]) questions [5, 8, 9].
Evidence-based CPGs should require minimal inter-
pretation by end-users, to reduce the risk of bias.
However, this type of CPG also carries inherent draw-
backs and limitations, including a potential disconnec-
tion between the focus on high-quality scientific
evidence and real-world clinical practice [10]. Evidence-
based guidelines may not address areas where there is
an insufficient number of well-designed clinical trials
(i.e. evidence), but yet clinicians still require guidance
in these areas [11].
While rigorous methodologies such as the GRADE
strategy offer robust and less biased treatment recom-
mendations, solely relying on such strict methodologies
can also compromise the conclusions and external valid-
ity of CPGs. Using high-level, formal methodology to de-
velop guidelines may exclude clinically relevant study
results [12]. Evidence-based guidelines may reduce pro-
fessional autonomy or clinical judgement [11]. Further-
more, the evidence included in these grading processes
is primarily collected from specific subsets of patients
who meet strict inclusion criteria for participation in
large clinical trials: specifically, registration randomised
controlled trials (RCTs) recruit patients in whom there
is the highest chance to demonstrate the efficacy of
tested agents [10]. Consequently, often the results ob-
tained do not allow determination of (i) the generalis-
ability of results obtained in selected populations, or (ii)
the most suitable target subgroups in terms of benefit-
risk ratio. However, it is well-recognised that significant
heterogeneity exists among patients with COPD. Older
or very severe COPD patients, patients with a history of
asthma and/or allergy, never smokers or patients with
multiple comorbidities may not meet inclusion criteria
and therefore may not be represented by the evidence
used to support most recommendations within guide-
lines [3, 11]. A recent study by Halpin et al. reported
that only 27% of COPD patients are eligible for RCTs
[13]. Under-representation of “challenging patients” (i.e.
those who do not meet strict eligibility criteria, particu-
larly the elderly, those with significant comorbidities and
those requiring long-term oxygen therapy) in RCTs
results in evidence-based CPGs that may not be fully
adequate to ensure the optimal management of a signifi-
cant number of patients.
Conversely however, guidelines which rely heavily on
consensus opinion, rather than high-quality evidence,
may be vulnerable to bias and individual interpretation
[11]. To try to find the right balance, evidence from real-
world effectiveness studies should be more heavily
considered in CPGs. These could include the results of
observational studies or pragmatic trials where appropri-
ate [10], provided that they satisfy appropriate quality
standards [14]. In light of this, CPGs should ideally
combine both evidence- and opinion-based approaches
in a complementary and transparent way. This can be
achieved by clearly highlighting sections that are evidence-
based, and addressing gaps in the knowledge by educated
opinion or extrapolation from efficacy evidence in other
disease areas. Furthermore, of significant consideration is
the use of single-disease guidelines for patients with mul-
tiple comorbidities. This may be particularly relevant in
the case of COPD, because due to the advanced age of the
majority of patients and the exposure to noxious particles
or gases, especially tobacco smoking, the prevalence of co-
morbidities is substantial [15]. In addition, COPD and its
respiratory consequences can exert direct deleterious ef-
fects on other systems; one example is the effect of lung
hyperinflation on heart function [16]. Conversely, some
comorbidities can increase the burden of COPD; e.g., anx-
iety and depression can increase the perception of dyspnea
through various mechanisms including hyperventilation
and psychological distress [17]. The frequency and type of
comorbidities presented may be different in patients in
real life compared to those included in RCTs [18]; there-
fore, guidance on multimorbidity will need to be consid-
ered in the future [19–21].
Guidelines are time-consuming and expensive to pro-
duce. Extensive literature reviews and detailed analyses
require more time and resources than clinical and aca-
demic experts can dedicate to the development and up-
dates of national or international CPGs [12, 22–24].
This puts strain on local and national societies with lim-
ited funding. Budget and available resources are import-
ant factors for most countries when developing and
updating their national guidelines [22]. Financial support
from private (e.g. pharmaceutical) companies may raise
issues around potential conflicts of interest [24]. New
simplified strategies for CPG development are being
tested; they combine consensus through a Delphi meth-
odology with strict application of GRADE in areas where
consensus is not reached or that are subject to a high
risk of bias [25]. If adequately validated, these strategies
could save significant time and resources. An overview
of the developmental processes for national CPGs in
Europe and Russia is presented in Table 1.
The key target audiences of national and international
guidelines
Identifying the key target audience is a critical step in
the development of CPGs. The audience is broad, and
includes healthcare practitioners with varying levels of
specialisation and expertise, as well as non-healthcare
professionals [26]. Pulmonologists, general practitioners
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(GPs), other healthcare professionals, patients, payors
and policy-makers are the primary audiences of COPD
guidelines.
Although not directly involved in the delivery of pa-
tient care, healthcare payors, policy-makers and regu-
latory agencies also comprise the readership of CPGs.
Recommendations that relieve the burden of disease
(e.g. reduce the frequency or severity of costly exacer-
bations) or strategies to encourage early diagnosis in
COPD patients can be of considerable benefit to
payors. Payors rely on CPGs and robust efficacy evi-
dence in order to make informed decisions on fund-
ing and reimbursement policies of specific therapies
[27, 28]. Policy-makers also need CPGs to develop ad-
equate prevention strategies and to build pathways of
care [29]. Guidelines are heavily regarded by regula-
tory authorities, which may impact the design of
clinical trials. This is of significant importance when
regulatory authorities adopt the definition or diagnos-
tic criteria used by a particular guideline when defin-
ing the requirements for novel drugs, thereby (and
perhaps inadvertently) influencing the design of
clinical trials [30].
Who is involved in the development of CPGs?
Guidelines that are intended for widespread use in clin-
ical practice should include relevant stakeholders at vari-
ous and appropriate stages of the development process,
which may encourage improved implementation and ad-
herence of the recommendations through an increased
sense of ownership [31, 32]. Although it may not be ap-
propriate for all stakeholders to take an active role in the
development process from the beginning, certain groups
may participate in the drafting of recommendations or
at the review stages.
Academic or clinical expert involvement in guideline
preparation should include GPs, pulmonologists, nurses
and physiotherapists where appropriate [31]. As the ma-
jority of COPD care is administered by GPs, their in-
volvement in guideline development may drive increased
primary care physician-specialist communication and in-
tegration, which is crucial in the management of COPD,
particularly when patient referral is necessary. Input
from nurses, cardiologists, physiotherapists and dieti-
cians may also add value and clinical expertise to guide-
lines in the pathways of care [26].
Importantly, guidelines should involve all “end-users”,
including patients, non-expert practitioners and payors
to ensure that the guidelines address the right questions
from a family or society perspective. Critically, this may
also help to incorporate patient preferences into the
guidelines. Increased involvement may encourage pa-
tients to play a more active role in their healthcare
management [33].
A standardised pan-European guideline; is this realistic?
Duplicate efforts are made across Europe, with individ-
ual countries investing significant resources into the de-
velopment of CPGs [34]. Institutional collaboration and
consolidation of efforts may significantly reduce the
cumbersome nature of guideline development and
frequent updates [35]. Furthermore, variations in
individual sets of guidelines will inevitably continue
unless collaboration is encouraged and optimised be-
tween countries. These variations, however minor,
have the potential to mislead or confuse practicing
healthcare professionals [10].
Most national guidelines in Europe have been influ-
enced to varying extents by GOLD. Moreover, GOLD
2017 [36] will likely impact future revisions of European
national guidelines in a move towards more personalised
treatment of COPD. The GOLD strategy also carries a
major positive advantage in that the document is
updated annually with the most recent and relevant lit-
erature and studies; however, no formal evaluation of
evidence (i.e. GRADE or similar) is performed. In
addition, since by its definition, GOLD aims to provide a
global strategy document, some recommendations may
not be directly (i.e. without any adaptation) applicable in
some areas or contexts. As most countries do not have
the resources to facilitate an annual update to their na-
tional guidelines, each country has the opportunity to
adopt specific sections of GOLD that are locally relevant.
Such processes could be facilitated by tighter collabor-
ation between GOLD committees and regional, national
or local initiatives.
Owing to the importance of national guidelines, coupled
with the international availability of the GOLD 2017 docu-
ment, there may be potential for the development of an
intermediary document between the two. This could com-
prise a single detailed “umbrella” evidence base supporting
common principles but with an adaptation of recommen-
dations to reflect local practices. Individual sensitivities
could therefore be facilitated within this common adapt-
able template. National reimbursement policies, availabil-
ity of resources and/or regulatory legislation may cause
guideline recommendation and prescription deviations
between countries. In brief, first-line treatment recom-
mendations (at the class level) and secondary recommen-
dations could be included within the common guideline,
with local alternative suggestions added at a local level in
line with local policy and scientific societies.
To support the introduction and implementation of
a common, adaptable European guideline, a pan-
European guideline development resource repository
could be compiled as a support tool. Moreover, differ-
ent sections of a guideline dedicated to a specific
healthcare practitioner role may boost implementation
across clinical practice.
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There is potential for significant alleviation of time
and budget constraints through a concerted, collabora-
tive effort between European countries. Who should take
the lead during such a collaboration remains to be
discussed, but it is likely that the European Respiratory
Society (ERS) is in the best position to lead such a pro-
ject. The ERS is committed to the development of high
quality CPGs [37], and either alone or in concert with
sister societies such as the American Thoracic Society
(ATS), has also delivered evidence-based CPGs for the
management of COPD [38, 39]. Developing a European
collaboration would be best achieved through the ERS
and national societies, agreeing on a common method-
ology. Tight links with the GOLD group could also be
useful to share retrieved evidence and increase reactivity,
allowing a continuous update and adaptation process.
Can COPD guidelines be simplified?
There is an apparent contradiction between the expo-
nential increase in the scientific knowledge of COPD
complexity (phenotypes, endotypes, comorbidities etc.)
and the need for simplified treatment pathways. Com-
plex raw data needs to be aggregated and translated into
meaningful, useful information to support recommenda-
tions of new treatments [29]. Algorithms may be helpful
to guide COPD therapy in a simple, stepwise and coordi-
nated manner [40]. Such algorithms need to be flexible
and continuously evolving in order to remain up-to-date
and clinically relevant. Importantly, the availability of al-
gorithms does not negate the need for scientific princi-
ples, and the role of clinical judgement should always be
acknowledged.
Considerations for effective guideline dissemination
Once finalised, the CPGs should be shared in many ways
to ensure optimal dissemination. Freely accessible online
publishing of the guidelines is important. A way forward
could be to amalgamate CPGs on all diseases into one
single portal that is accessible by all physicians, other
healthcare professionals and the general public free of
charge. This has been done in Finland by the general
Medical Society Duodecim Current Care Guideline
system where guidelines on more than 100 diseases are
collated on a single online portal and used by most
healthcare professionals [41]. Also, presenting the guide-
lines at local, national and international congresses may
increase awareness amongst a myriad of healthcare prac-
titioners. Furthermore, innovative methods to inform
relevant end-users of CPGs could be considered e.g. e-
mail blasts or social media communications. Plain
language summaries may also prove helpful to guide pa-
tients and their relatives on available treatments. A short
pocket version should be made available to all physicians
to facilitate quick and easy access during patient
consultations. Useful treatment algorithms should be
available on an easily-navigable website. Using smart
technology may also improve the implementation of
guidelines. Such applications may also have a place
within already-existing clinical integrated management
systems such as GP practice computer software.
The final presentation of the recommendations should
also be carefully considered. Succinct and concise rec-
ommendations presented in an easily-digestible format
such as tables or charts should be considered for busy
healthcare practitioners [10].
Conclusions
Evidence-based CPGs are rigorous by their very nature,
but are difficult to implement in real-life clinical practice
[11]. Some suggestions for improvement in the develop-
ment and implementation of COPD CPGs are presented
in Table 2. The authors suggest that an ideal COPD
guideline document should comprise a fair balance be-
tween evidence-based and expert opinion-based recom-
mendations where definitive evidence is unavailable. For
transparency, each recommendation should clearly state
whether it is supported by evidence or based on expert
opinion and clinical judgement.
The key target medical audience of COPD guidelines
include pulmonologists and GPs, with patients, payors
and policy-makers also comprising the intended audi-
ence. All end-users should be involved in the develop-
ment of guidelines. Formally assessing what they expect
from the guidelines and which barriers may impede their
implementation could help overcome current insuffi-
ciencies in routine care for COPD patients.
Some guideline developers struggle to provide the ne-
cessary resources to support the development and/or
Table 2 Suggestions for improvement in the development and
implementation of COPD guidelines
Development of CPG must be based on a validate method of
evaluation and grading of evidence (GRADE or similar)
In areas in which GRADE may not be applied, consensus or
opinion-based recommendations should be incorporated
A clear identification of evidence-based and consensus-based
recommendations is mandatory for transparency
Clear and simple algorithms are necessary for interpretation and
implementation
All stakeholders must participate in CPGs development
A common European guideline could be used as a reference and
can be adapted to local health systems
The European Respiratory Society could be the platform to
generate and discuss national European CPGs
Dissemination and adherence is crucial and new technologies may
help to this objective
New studies are required to evaluate the impact of CPGs on clinical
and economic outcomes in COPD
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regular update of their guidelines. Furthermore, it is pos-
sible that not all aspects of international guidelines will
be directly relevant to all local patients. In this regard,
improved collaboration between European countries and
the ERS may be beneficial, where a single intermediary
strategy document for the management of COPD should
be considered. This document could encompass some
overarching high-level common principles, with the im-
portant opportunity for local adaptation. This may sig-
nificantly reduce the costs and resources associated with
guideline development for many countries.
Although the majority of COPD management is con-
ducted by GPs, familiarity of guidelines amongst general
practitioners is suboptimal. Approximately 24% of gen-
eral practitioners have reported that they are not familiar
with the GOLD strategy for COPD [42].
Quick and easy access to guidelines on a website or
smart phone is important to maximise guideline imple-
mentation. A quickly- and easily-understandable treat-
ment algorithm may help to simplify COPD guidelines.
The algorithm must be flexible and continually evolving
in accordance with new research and evidence.
There is still a paucity of knowledge on the effect of
adequate COPD guideline implementation on disease
management and patient outcomes. Further studies are
warranted to address this gap in the literature.
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